Skip to content
  • Home
  • About us
  • Clinical trials
  • Blog
  • Contact us
  • Home
  • About us
  • Clinical trials
  • Blog
  • Contact us
Get started
icon
icon

icon
icon
icon Medical trials / View details
cancle-icon

Endobronchial Ultrasound-guided Transbronchial Needle Aspiration for Lymph Node Staging in Patients With Non-small Cell Lung Cancer Pursuing Stereotactic Body Radiotherapy (SBRT)

Contact information

icon Judy McConnell

icon Toronto General Hospital

icon Toronto, Ontario, Canada, M5G 1L7

Basic information

icon

icon 18-30, 31-40, 41-50, 51-60, 61-70, Over 70 Age

icon 150 Enrollment

icon
Lung Cancer
Trial Details
Brief Summary

It is reported that more than 90,000 patients died of lung cancer and more than 20% of them were older than 80 years in North America. Therefore a less invasive but effective treatment is required for patients with lung cancer of advanced age, diminished pulmonary functions, and chronic diseases. Stereotactic body radiation therapy (SBRT) is an effective and well-tolerated treatment for early stage lung cancer in medically inoperable patients. On the other hand, accurate mediastinal and hilar lymph node staging is one of the most important factors that determine the outcome and indications for SBRT. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a novel, minimally invasive modality that enables the assessment of mediastinal and hilar lymph nodes with a high sensitivity. Accurate lymph node staging by EBUS-TBNA will allow opportunities for high-risk patients with lung cancer to undergo minimally invasive treatment.

Official Title

Endobronchial Ultrasound-guided Transbronchial Needle Aspiration for Lymph Node Staging in Patients With Non-small Cell Lung Cancer Pursuing Stereotactic Body Radiotherapy (SBRT)

Selection Criteria
Eligibility Inclusion Criteria
    - Age 18 years or older
    - Patients with confirmed lung cancer who require EBUS-TBNA as part of their staging investigations of the mediastinum and hilum prior to SBRT
    - Performance status score (WHO/ECOG) of 0-2.
    - Cytological or histological proof of non-small cell cancer
    - Stage T1-2 disease, with no evidence of distant metastasis
    - Patients are screened by both computed tomography (CT) and positron emission tomography (PET)
    - Medically inoperable for surgical resection
    - Patients who refused surgery
Eligibility Exclusion Criteria
    - Patients who are deemed on clinical grounds not to be medically fit for a bronchoscopy
    - Active systemic, pulmonary, or pericardial infection
    - Patients who are pregnant or lactating
    - Patients with plans to receive conventional radiotherapy, chemotherapy, biological therapy, vaccine - therapy, or surgery as treatment (except at disease progression).
    - Inability to give informed consent

Join us! Be part of the smart work revolution.

Explore articles with tips and insights to know your about clinical matching

Contact us
Navigation
  • Home
  • About us
  • Clinical trials
  • Blog
  • Home
  • About us
  • Clinical trials
  • Blog
Address

L1N6Y1 / 26

Winston Crescent

Whitby, ON

Canada

Legal
  • Terms of use
  • Privacy Policy
  • Contact us
  • Terms of use
  • Privacy Policy
  • Contact us
Contact
+1 587-664-4986 info@horizonnt.ca
Get in touch
Horizon trial
  • Home
  • About us
  • Clinical trials
  • Blog
  • Contact us
  • Home
  • About us
  • Clinical trials
  • Blog
  • Contact us
Get started